Actively Recruiting
ROS-Scavenging Nanozyme Combined With Thermotherapy Alleviate Radiation Dermatitis in Patients With Head and Neck Cancer
Led by West China Hospital · Updated on 2026-04-15
5
Participants Needed
1
Research Sites
65 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Severe radiation dermatitis remains a challenging complication in head and neck cancer with limited treatment options; this study aims to evaluate a novel Prussian blue-based nanozyme combined with near-infrared thermotherapy to promote effective healing of Grade III lesions.
CONDITIONS
Official Title
ROS-Scavenging Nanozyme Combined With Thermotherapy Alleviate Radiation Dermatitis in Patients With Head and Neck Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a pathological diagnosis of non-metastatic head and neck malignant tumors
- Patients suitable for high-dose radiotherapy as primary or postoperative treatment
- Adults aged 18 to 80 years
You will not qualify if you...
- Eastern Cooperative Oncology Group performance status greater than 2
- Pre-existing skin rash, ulceration, or open wound in the treatment area
- Known allergy to trolamine or Prussian blue
- Inflammatory or connective tissue disorder of the skin
- History of head and neck radiotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sichuan University West China Hospital
Chengdu, Sichuan, China
Actively Recruiting
Research Team
X
Xingchen Peng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here